JP5769616B2
(ja)
|
2008-04-30 |
2015-08-26 |
イミュノジェン・インコーポレーテッド |
クロスリンカーおよびそれらの使用
|
GB0819095D0
(en)
*
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
EP3100745B1
(de)
|
2009-02-05 |
2018-04-18 |
Immunogen, Inc. |
Neuartige benzodiazepinderivate
|
SG10201810743WA
(en)
|
2009-06-03 |
2018-12-28 |
Immunogen Inc |
Conjugation methods
|
JP5870400B2
(ja)
|
2010-04-15 |
2016-03-01 |
シアトル ジェネティクス,インコーポレーテッド |
標的化ピロロベンゾジアゼピンコンジュゲート
|
BR112012026410B8
(pt)
|
2010-04-15 |
2023-01-31 |
Spirogen Dev Sarl |
Composto e conjugado de pirrolobenzodiazepinas e usos dos mesmos
|
KR20140010067A
(ko)
|
2011-02-15 |
2014-01-23 |
이뮤노젠 아이엔씨 |
컨쥬게이트의 제조방법
|
KR101860174B1
(ko)
*
|
2011-09-20 |
2018-05-21 |
메디뮨 리미티드 |
표적 접합체 내의 내포를 위한 비대칭 이량체 pbd 화합물로서 피롤로벤조디아제핀
|
CN103987384A
(zh)
|
2011-10-14 |
2014-08-13 |
西雅图基因公司 |
吡咯并苯并二氮杂卓和靶向结合物
|
WO2013053873A1
(en)
|
2011-10-14 |
2013-04-18 |
Spirogen Sàrl |
Pyrrolobenzodiazepines
|
EP2751110B1
(de)
|
2011-10-14 |
2017-04-19 |
MedImmune Limited |
Asymmetrische Bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-on) Derivate zur Behandlung von proliferativen oder Autoimmunerkrankungen
|
WO2013055993A1
(en)
|
2011-10-14 |
2013-04-18 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
CA2869557A1
(en)
|
2012-04-06 |
2013-10-10 |
Indus Pharmaceuticals, Inc. |
Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment
|
WO2013165940A1
(en)
|
2012-05-01 |
2013-11-07 |
Genentech, Inc. |
Anti-pmel17 antibodies and immunoconjugates
|
IN2014DN10652A
(de)
|
2012-07-09 |
2015-09-11 |
Genentech Inc |
|
AU2013288929A1
(en)
|
2012-07-09 |
2014-12-04 |
Genentech, Inc. |
Immunoconjugates comprising anti-CD22 antibodies
|
EP2906249B1
(de)
|
2012-10-12 |
2018-06-27 |
MedImmune Limited |
Synthese und zwischenprodukte pyrrolobenzodiazepinderivaten zur konjugation
|
CN110256469B
(zh)
|
2012-10-12 |
2022-05-17 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
RS56520B1
(sr)
|
2012-10-12 |
2018-02-28 |
Adc Therapeutics Sa |
Pirolobenzodiazepin-anti-cd22 konjugati antitela
|
PL2906253T3
(pl)
|
2012-10-12 |
2019-02-28 |
Adc Therapeutics Sa |
Koniugaty pirolobenzodiazepina-przeciwciało anty-psma
|
EP2906296B1
(de)
|
2012-10-12 |
2018-03-21 |
ADC Therapeutics SA |
Pyrrolobenzodiazepin-antikörper-konjugate
|
WO2014057114A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
US9931414B2
(en)
|
2012-10-12 |
2018-04-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
US10695433B2
(en)
|
2012-10-12 |
2020-06-30 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
LT2839860T
(lt)
|
2012-10-12 |
2019-07-10 |
Medimmune Limited |
Pirolobenzodiazepinai ir jų konjugatai
|
ES2701076T3
(es)
|
2012-11-24 |
2019-02-20 |
Hangzhou Dac Biotech Co Ltd |
Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
|
CN110452242A
(zh)
|
2012-12-21 |
2019-11-15 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
JP6527466B2
(ja)
|
2012-12-21 |
2019-06-05 |
メドイミューン・リミテッドMedImmune Limited |
増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
JP6436965B2
(ja)
|
2013-03-14 |
2018-12-12 |
ジェネンテック, インコーポレイテッド |
抗b7−h4抗体及びイムノコンジュゲート
|
MX2016003248A
(es)
|
2013-09-17 |
2016-06-07 |
Genentech Inc |
Metodos de uso de anticuerpos anti-lgr5.
|
US9956299B2
(en)
|
2013-10-11 |
2018-05-01 |
Medimmune Limited |
Pyrrolobenzodiazepine—antibody conjugates
|
EP3054983B1
(de)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepin-antikörper-konjugate
|
EP3054985B1
(de)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepin-antikörper-konjugate
|
GB201317981D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
CA2931340A1
(en)
|
2013-12-13 |
2015-06-18 |
Genentech, Inc. |
Anti-cd33 antibodies and immunoconjugates
|
CN114262344A
(zh)
|
2014-02-28 |
2022-04-01 |
杭州多禧生物科技有限公司 |
带电荷链接体及其在共轭反应上的应用
|
RU2016150370A
(ru)
|
2014-05-22 |
2018-06-26 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты против GPC3
|
RU2764074C2
(ru)
|
2014-08-28 |
2022-01-13 |
Байоатла, Ллк |
Условно активные химерные антигенные рецепторы для модифицированных т-клеток
|
AU2015314744A1
(en)
|
2014-09-12 |
2017-03-02 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
MA40576B1
(fr)
|
2014-09-12 |
2020-11-30 |
Genentech Inc |
Anticorps et immunoconjugués anti-her2
|
AU2015314826A1
(en)
|
2014-09-12 |
2017-03-02 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
CN113698488A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
EP3197500A1
(de)
|
2014-09-17 |
2017-08-02 |
Genentech, Inc. |
Immunkonjugate mit anti-her2-antikörpern und pyrrolobenzodiazepinen
|
US10780096B2
(en)
|
2014-11-25 |
2020-09-22 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
NZ739830A
(en)
|
2015-07-12 |
2021-12-24 |
Hangzhou Dac Biotech Co Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
CN108026103B
(zh)
|
2015-07-21 |
2021-04-16 |
伊缪诺金公司 |
制备细胞毒性苯并二氮杂䓬衍生物的方法
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
EP3443012A4
(de)
|
2016-04-15 |
2019-09-11 |
Bioatla, LLC |
Anti-axl-antikörper, antikörperfragmente und deren immunkonjugate und verwendungen davon
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
RS63698B1
(sr)
|
2016-05-13 |
2022-11-30 |
Bioatla Inc |
Anti-ror2 antitela, fragmenti antitela, njihovi imunokonjugati i njihove upotrebe
|
EP3465221B1
(de)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytisches verfahren zur charakterisierung von ortsspezifischen antikörper-wirkstoff-konjugaten
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
US11066479B2
(en)
|
2016-08-02 |
2021-07-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
JP2019530434A
(ja)
|
2016-08-05 |
2019-10-24 |
ジェネンテック, インコーポレイテッド |
アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
|
CN109689111B
(zh)
|
2016-08-11 |
2024-04-05 |
基因泰克公司 |
吡咯并苯并二氮杂䓬前药及其抗体缀合物
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
KR20220147721A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
AU2017361887B2
(en)
|
2016-11-21 |
2019-08-15 |
Cureab Gmbh |
Anti-GP73 antibodies and immunoconjugates
|
US11236171B2
(en)
|
2016-12-21 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
JP6671555B2
(ja)
|
2017-02-08 |
2020-03-25 |
アーデーセー セラピューティクス ソシエテ アノニム |
ピロロベンゾジアゼピン抗体複合体
|
AU2018255876B2
(en)
|
2017-04-18 |
2020-04-30 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
US20200129637A1
(en)
|
2017-04-20 |
2020-04-30 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
EP3625256A1
(de)
|
2017-05-19 |
2020-03-25 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Humaner monoklonaler antikörper gegen tnfr2 zur krebsimmuntherapie
|
AU2018285562B2
(en)
|
2017-06-14 |
2024-01-18 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-CD19 ADC
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
AU2018316532B2
(en)
|
2017-08-18 |
2022-11-24 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
CA3125713A1
(en)
|
2017-09-29 |
2019-04-04 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
JP7459043B2
(ja)
|
2018-07-12 |
2024-04-01 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
親和性成熟cd22特異的モノクローナル抗体およびその使用
|
CN112585163A
(zh)
|
2018-08-08 |
2021-03-30 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向磷脂酰肌醇蛋白聚糖-2的高亲和力单克隆抗体及其用途
|
EP3883608A1
(de)
|
2019-01-08 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Speziesübergreifende einzeldomänenantikörper gegen mesothelin zur behandlung von soliden tumoren
|
CN113784987A
(zh)
|
2019-01-22 |
2021-12-10 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
|
AU2020370125A1
(en)
|
2019-10-22 |
2022-05-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting B7H3 (CD276) for treating multiple solid tumors
|
EP4041769A1
(de)
|
2019-12-12 |
2022-08-17 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Antikörper-wirkstoff-konjugate spezifisch für cd276 und deren verwendungen
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
CA3216228A1
(en)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|